MedComm – Oncology Journal Specifications
Overview | |
Publisher | Wiley |
Language | English |
Article Processing Charges | USD 2800 |
Publication Time | 15 |
Editorial Review Process | Anonymous peer review |
General Details | |
Language | English |
Society/Institute/Sponsor | Sichuan International Medical Exchange & Promotion Association (SCIMEA) |
Website URL | Visit website |
Publication Details | |
Editorial Review Detail | |
Information for authors | |
Author instructions | Visit website |
Copyright Details | Visit website |
Deposit Policy | Sherpa/Romeo |
License type | CC BY |
OA statement | Visit website |
View less![](https://cdn.researcher.life/rlife/icons/arrow-down-blue.svg)
Looking for the right journals to submit your mansucript?
Upload your manuscript and get a submission readiness score and other journal recommendations.
Check my PaperRecently Published Papers in MedComm – Oncology
Title not available
- 1 Sep 2024
- MedComm – Oncology
Next‐generation sequencing identifies that protein tyrosine phosphatase receptor type D mutation is favorable to immunotherapy in human cancer
- 7 Jul 2024
- MedComm – Oncology
Next‐generation sequencing identifies that protein tyrosine phosphatase receptor type D mutation is favorable to immunotherapy in human cancer
- 7 Jul 2024
- MedComm – Oncology
Issue Information
- 2 Jul 2024
- MedComm – Oncology
Clinical homologous recombination repair gene reversion analysis identifies mechanisms of resistance to PARP inhibitors and platinum‐chemotherapy
- 1 Jun 2024
- MedComm – Oncology
Targeting werner helicase with synthetic lethality in microsatellite instability cancers: Promising therapeutic approaches
- 1 Jun 2024
- MedComm – Oncology
Title not available
- 1 Sep 2024
- MedComm – Oncology
Next‐generation sequencing identifies that protein tyrosine phosphatase receptor type D mutation is favorable to immunotherapy in human cancer
- 7 Jul 2024
- MedComm – Oncology
Next‐generation sequencing identifies that protein tyrosine phosphatase receptor type D mutation is favorable to immunotherapy in human cancer
- 7 Jul 2024
- MedComm – Oncology
Issue Information
- 2 Jul 2024
- MedComm – Oncology
Clinical homologous recombination repair gene reversion analysis identifies mechanisms of resistance to PARP inhibitors and platinum‐chemotherapy
- 1 Jun 2024
- MedComm – Oncology
Targeting werner helicase with synthetic lethality in microsatellite instability cancers: Promising therapeutic approaches
- 1 Jun 2024
- MedComm – Oncology
FAQs on MedComm – Oncology
How many articles did MedComm – Oncology publish last year? ![Faqs](https://cdn.researcher.life/rlife/icons/arrow-down.svg)
In 2023, MedComm – Oncology publsihed 46 articles.
Who is the publisher of MedComm – Oncology? ![Faqs](https://cdn.researcher.life/rlife/icons/arrow-down.svg)
Wiley is the publisher of MedComm – Oncology.